Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
latest decrease » greatest decrease (Expand Search), largest decreases (Expand Search), latency decreased (Expand Search)
stat decrease » step decrease (Expand Search), small decrease (Expand Search), a decrease (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
latest decrease » greatest decrease (Expand Search), largest decreases (Expand Search), latency decreased (Expand Search)
stat decrease » step decrease (Expand Search), small decrease (Expand Search), a decrease (Expand Search)
-
261
-
262
-
263
Supplementary Material for: Protein inhibitor of activated STAT 2 (PIAS2) protects against podocyte injury in diabetic nephropathy via inhibiting JAK2/STAT3 pathway
Published 2025“…Recombinant human IL-6 was used as an agonist of the JAK2/STAT3 signaling pathway to further validate the mechanism of the effects of PIAS2 in high glucose induced human podocytes. …”
-
264
-
265
-
266
-
267
-
268
-
269
-
270
-
271
The correlogram.
Published 2025“…Results demonstrated that groups with a lower prevalence of diabetes showed lower dietary EFP, while the dietary EFP and GHG emissions peaked among the prediabetes group with a prevalence of 32.7%−34.9%, and then decreased significantly with the increasing prevalence of prediabetes. …”
-
272
The food consumption quantity.
Published 2025“…Results demonstrated that groups with a lower prevalence of diabetes showed lower dietary EFP, while the dietary EFP and GHG emissions peaked among the prediabetes group with a prevalence of 32.7%−34.9%, and then decreased significantly with the increasing prevalence of prediabetes. …”
-
273
Dataset.
Published 2025“…Results demonstrated that groups with a lower prevalence of diabetes showed lower dietary EFP, while the dietary EFP and GHG emissions peaked among the prediabetes group with a prevalence of 32.7%−34.9%, and then decreased significantly with the increasing prevalence of prediabetes. …”
-
274
-
275
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
276
-
277
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
278
-
279
-
280